Global Hydroxychloroquine Market By Type (Tablet and Active Pharmaceutical Ingredients), By Disease Indication (Malaria, Lupus Erythematosus, COVID-19, Rheumatoid Arthritis, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

In 2022, the Global Hydroxychloroquine Market was valued at US$ 1,275 Million. Between 2023 and 2032, this market is estimated to register a CAGR of 20.60%.

Hydroxychloroquine is in a class of drugs called antimalarial, which is used to prevent and treat malaria in areas where malaria remains sensitive to Chloroquine. Hydroxychloroquine is used as a first-line treatment for diseases such as malaria, rheumatoid arthritis, and other autoimmune disorders. It is an anti-parasite and immunosuppressive drug indicated for the treatment of malaria.

Recently, hydroxychloroquine has attracted attention owing to its effectiveness in treating patients with COVID-19. Increasing requirements for new hydroxychloroquine and increasing penetration of generic drugs are anticipated to improve the market.

Global Hydroxychloroquine Market Scope

Type Analysis

Active Pharmaceutical Ingredients Segment to Witness Significant Growth

The global hydroxychloroquine market is segmented based on type into tablet and active pharmaceutical ingredients. The active pharmaceutical ingredients segment accounted for the largest market share of 53% during the forecast period due to their responsibility for the beneficial health effects experienced by consumers.

They are biologically active or directly affect disease treatment, diagnosis, cure, and prevention. However, the tablet segment is recognized for the easy accessibility of the product in tablet form, therefore, is anticipated to develop at a larger CAGR. Additionally, the rise in the high requirement for tablets due to cost-effectiveness and facility of consumption boosted the hydroxychloroquine market growth.

By Disease Indication Analysis

The Malaria Segment Dominated the Market Growth of the Hydroxychloroquine Market

Based on disease indication, the global hydroxychloroquine market is divided into malaria, COVID-19, Lupus Erythematosus, Rheumatoid Arthritis, and others. The malaria segment registers the maximum market share. It is anticipated to grow at a steady CAGR during the forecast period due to the rising dominance of malaria in underdeveloped and developing countries.

Furthermore, there are still countries in African regions considered malaria endemic. Hydroxychloroquine is also listed as an essential medicine by WHO. However, COVID-19 disease indication is anticipated to record the fastest CAGR in the market due to the current disease outbreak caused by the new coronavirus.

By Distribution Channel Analysis

Hospital Pharmacy Segment Accounted for Dominant Share of the Market

Based on distribution channels, the global hydroxychloroquine market is classified into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacy section dominated the market share growth and generated the highest revenue share during the forecast period. This is mainly recognized by the growing government advantages to treat malaria in rural areas of underdeveloped and developed countries.

The retail pharmacy segment is projected to fuel during the forecast period, primarily owing to the substantial development in healthcare infrastructure in emerging countries. Furthermore, the development of the online store’s segment will likely be determined by the rising permeation of attractive discounts, e-commerce, and coupons accessible through online channels.

Key Market Segments

By Type

• Tablet
• Active Pharmaceutical Ingredients

By Disease Indication

• Malaria
• Rheumatoid Arthritis
• COVID-19
• Lupus Erythematosus
• Other Disease Indications

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Market Dynamics

Drivers

The growing Incidence of Malaria in Emerging Asian Countries is Anticipated to Boost the Hydroxychloroquine Market.

In the previous few years, there has been a rise in the prevalence of malaria in the emerging countries of Asia-Pacific. India is anticipated to have the region’s most significant number of malaria cases. Hydroxychloroquine is amongst the maximum expended drugs opposed to malaria in the country.

According to the World Malaria Report data, millions of individuals were identified with malaria in India only. According to World Health Organization, worldwide, anticipated millions of individuals suffer from malaria.

The rise in the Spread of COVID-19 Worldwide is Anticipated to Drive the Market.

According to the WHO, there are millions of active cases of COVID-19 caused by the new coronavirus and anticipated related deaths of many individuals. Since there is no specific treatment in the market to treat coronavirus and the vaccine against the disease will demand more than 18 months to come to market, healthcare professionals have applied to approve different drugs for disease control and management.

One such possibility was shown by hydroxychloroquine. Specific studies that were led in various countries used the drug in patients affected with COVID-19. The results displayed the encouraging consequences amongst patients prescribed the drugs. An increase in the prevalence of malaria and rheumatoid arthritis and a rise in the geriatric population are expected to drive market growth.

Restraints

Adverse Effects Related to the Use of Hydroxychloroquine Will Hinder Market Growth

One of the major factors hindering the hydroxychloroquine market growth is the adverse effects related to the drug. Moreover, its clinical efficiency through randomized clinical is not considered for side effects in COVID-19 disease indication. Therefore, the inconsistency of long-term side effects of drug use in treating COVID-19 is anticipated to restrain the market during the forecast period.

In addition, studies showed that this drug has adverse effects such as stomach aches, diarrhea, and cardiac problems owing to continued use of the drug.

Opportunity

Increasing Penetration of Generic Drugs will act as an Opportunity.

The rise in requirement for novel hydroxychloroquine and increasing generic drug penetration are estimated to influence the market positively. For Example, In March, Novartis AG started delivering millions of hydroxychloroquine tablets to the U.S. Department of Health and Human Services to organize clinical trials to evaluate the effectiveness of hydroxychloroquine in patients with COVID-19 illness.

The enhanced government support is also projected to significantly influence the market penetration of increasing product approval.

Trends

Enhanced Importance by Manufacturers to Develop the Growth Opportunities in the COVID-19 Segment

The prominent manufacturers of hydroxychloroquine across the globe are utilizing the current outbreak of COVID-19 to increase their production and sale. In addition, studies in U.S. and France showed promising results for drug administration.

This has advised countries to import a high volume of hydroxychloroquine training to inhibit the spread of the virus. Owing to this rise in drug requirements, manufacturers have raised the production capabilities in their facilities.

COVID-19 Impact Analysis

The COVID-19 outbreak has raised the need for medication, leading to enormous market growth. Currently, hydroxychloroquine efficiency in treating COVID-19-infected patients has been attractive. According to Chinese sources, Chloroquine has been demonstrated to constrain SARS-CoV-2 in vitro.

Furthermore, the medication has been proven successful in treating COVID-19 patients. Therefore, the coronavirus medication hydroxychloroquine is thought to be an effective treatment for the COVID-19 pandemic.

Regional Analysis

North America Region Accounted Significant Revenue Share of the Global Hydroxychloroquine Market.

North America accounted for a significant hydroxychloroquine market revenue share of 40%. Owing to the region’s important product for manufacturing and development in healthcare infrastructure. High spending on R&D as well as the accessibility of qualified workers, will further accelerate the market growth rate in this area.

The Asia-Pacific region is anticipated to grow at a high rate in the forecast period. Due to expanded government awareness campaigns and rising healthcare investments in this area. Additionally, the increasing availability of generic medications will slow the market expansion in this area.

Key Regions and Countries Covered in this Report

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America

• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Market Share & Key Players Analysis

Acquisition of Johnson & Johnson Customers to Provide Leading Position in the Market

Due to the increasing cases of coronavirus infections across the globe, manufacturers have increased production capabilities in their manufacturing facilities. India is the prominent manufacturer of hydroxychloroquine globally and accounts for the highest market requirement. The prominent key players in the market include such as Zydus Cadila, Sanofi, IPCA Laboratories Ltd, Sandoz International GmbH., and others.

Recent Development

• June 2021- Catalent, Inc. pronounced that they would obtain RheinCell Therapeutics GmbH, a prominent inventor and manufacturer of GMP-grade human-encouraged pluripotent stem cells. This achievement will help the company’s prevailing stem cell therapy process manufacturing and development abilities.
• December 2020- Lonza announced that they had extended their partnership with Aurinia Pharmaceuticals to increase a manufacturing capability for the professional production and manufacturing of Voclosporin.
• July 2020- The USFDA was notified against using hydroxychloroquine and Chloroquine to administer hospitalized COVID-19 patients with coronavirus owing to the threat of heart rhythm problems, lymph system disease, liver problems, and kidney injuries.

The following are some of the major players in the global hydroxychloroquine market industry

• Sanofi S.A.
• Sandoz International GmbH
• Ipca Laboratories Limited
• Mylan N.V.
• Teva Pharmaceutical Industries Limited
• Bayer AG
• Zydus Lifesciences Limited
• Hikama Pharmaceuticals plc.
• Pfizer Inc.
• Torrent Pharmaceutical Ltd
• Zydus Pharmaceutical Inc.
• Amneal Pharmaceuticals LLC
• Torrent Pharmaceuticals Ltd
• Taj Pharmaceuticals Ltd.
• Cadila Healthcare Ltd.
• Cipla Inc.
• Accord Healthcare Inc.
• Other Key Player

Report Scope